Avaliação da eficácia de produto homeopático contendo Momordica charantia 12CH no controle dos sintomas do trato urinário inferior, causados pela hiperplasia benigna da próstata: ensaio clínico
The benign enlargement of the prostate, better known as benign prostatic hyperplasia (BPH) results in symptoms of the lower urinary tract (LUTS) that contributes to lower quality of life of men over the fourth decade, and is mostly treated by allopathic drugs of the group of 5-alpha-reductase inhibi...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | doctoralThesis |
| Idioma: | por |
| Publicado em: |
Brasil
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/jspui/handle/123456789/24519 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| Resumo: | The benign enlargement of the prostate, better known as benign prostatic hyperplasia (BPH) results in symptoms of the lower urinary tract (LUTS) that contributes to lower quality of life of men over the fourth decade, and is mostly treated by allopathic drugs of the group of 5-alpha-reductase inhibitors and / or alpha-blockers, and / or phytotherapics. The scientific literature shows lack research from randomised and doubleblind clinical trials on the efficacy of homeopathic medicinal products that already have homeopathic medical materia and new homeopathic medicinal for BPH.The present study aimed to evaluate the effectiveness of the homeopathic product containing Momordica charantia 12CH in the LUTS control caused by BPH in a clinical, randomized, double-blind and placebo-controlled trial.A total of 81 patients were randomized to group A - Placebo and group B - Momordica charantia 12CH and evaluated at each visit by anamnesis with the International Prostate Symptom Score (IPSS), by imaging tests measured prostate volume (PV) and post-void residual (PVR) and laboratory tests for prostate specific antigen (PSA), quantitative C-reactive protein (CRP) and interleukin-6 (IL-6), and in 72 samples, lymphocyte and subpopulation immunophenotyping were performed by flow cytometry.Both the main variable (IPSS) and the secondary variables (PSA, PV, PVR and CRP) and accessory variables (IL-6, total lymphocytes, B lymphocytes, T lymphocytes, T helper cells, cytotoxic T lymphocytes and CD4 / CD8 ratio and Natural Killer cells) did not present statistical significance in the means between the groups treated and Placebo.About the safety variables, the use of homeopathic medication by the patients did not interfere during the six months of research, either in the fasting glucose level, as well as in the dosages of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubins and fractions and creatinine levels used for hepatic evaluation and renal function respectively.The absence of urinary infection confirmed by urinalysis of patients predominated in both groups A and B throughout the clinical trial period. It can be concluded that treatment with Momordica charantia 12CH did not show a significant difference for placebo in the efficacy in the control of STUI by BPH, but it demostrated to be safe. High quality researchs, which allows prescription, from the individualization of symptoms and with different dynamizations, must be performed, to enable more decisiveinterpretation of its effectiveness. |
|---|